{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:23:13Z","timestamp":1789593793784,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Recurrent pancreatic ductal adenocarcinoma (PDAC) includes circulating tumor DNA (ctDNA)-defined molecular residual disease (MRD), isolated or oligometastatic relapse, disseminated measurable recurrence, and heavily pretreated refractory disease. These states differ in tumor burden, treatment urgency, tissue accessibility, and immune competence and should not be treated as one population. Immune checkpoint blockade has minimal activity in unselected PDAC, and randomized trials have not shown consistent benefit from adding checkpoint inhibitors to chemotherapy. However, rare microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) tumors and selected antigen- or human leukocyte antigen (HLA)-defined subgroups support precision immune intervention. This Mini Review evaluates biomarkers for immunotherapy and adoptive cell therapy, including ctDNA kinetics, tumor mutational burden, KRAS and neoantigen profiles, antigen presentation and target-antigen density, effector immune state, myeloid and fibroblast-mediated suppression, and spatial immune exclusion. It compares checkpoint blockade, personalized and KRAS-directed vaccines, chimeric antigen receptor T-cell (CAR-T), chimeric antigen receptor natural killer-cell (CAR-NK), and T-cell receptor (TCR)-engineered therapies by recurrence setting, evidence maturity, feasibility, and failure mechanisms. Checkpoint blockade is currently most defensible for MSI-H\/dMMR disease; vaccines and cell therapies remain investigational and are best tested in biomarker-selected trials, especially in low-burden or molecular recurrence. We propose a five-step workflow to classify recurrence, identify actionable biomarkers, match evidence-appropriate interventions, assess feasibility, and monitor response and immune escape. This framework supports trial design and disciplined clinical translation rather than empiric immunotherapy in unselected recurrent PDAC.<\/jats:p>","DOI":"10.3389\/fmed.2026.1900701","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:30:15Z","timestamp":1786620615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Tao","family":"He","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Huai\u2019an No. 1 People\u2019s Hospital of Nanjing Medical University","place":["Huai\u2019an, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoan","family":"Li","sequence":"additional","affiliation":[{"name":"The Affiliated Huai\u2019an No. 1 People\u2019s Hospital of Nanjing Medical University","place":["Huai\u2019an, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhen","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Huai\u2019an No. 1 People\u2019s Hospital of Nanjing Medical University","place":["Huai\u2019an, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1053\/j.gastro.2024.05.028","article-title":"Prognostic factors for early recurrence after resection of pancreatic cancer: a systematic review and meta-analysis","volume":"167","author":"Leonhardt","year":"2024","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"106910","DOI":"10.1016\/j.ejso.2023.04.009","article-title":"Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: a bi-institutional validated risk classification","volume":"49","author":"van Oosten","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jhbp.1282","article-title":"Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection","volume":"30","author":"Hata","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"27296","DOI":"10.1038\/s41598-024-76903-y","article-title":"Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients","volume":"14","author":"Maulat","year":"2024","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/curroncol32110589","article-title":"ctDNA in Pancreatic Adenocarcinoma: a critical appraisal","volume":"32","author":"Ojha","year":"2025","journal-title":"Curr Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European cohort","volume":"188","author":"Taieb","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e004485","DOI":"10.1136\/jitc-2021-004485","article-title":"Detection of microsatellite instability-high by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer","volume":"10","author":"Chakrabarti","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1383978","DOI":"10.3389\/fimmu.2024.1383978","article-title":"Frontiers and future of immunotherapy for pancreatic cancer","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","article-title":"Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial","volume":"17","author":"Huff","year":"2026","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1325860","DOI":"10.3389\/fimmu.2024.1325860","article-title":"Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report","volume":"15","author":"Zhong","year":"2024","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","article-title":"Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment","volume":"14","author":"Werba","year":"2023","journal-title":"Nat Commun"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41588-022-01157-1","article-title":"Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer","volume":"54","author":"Cui Zhou","year":"2022","journal-title":"Nat Genet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-024-02050-7","article-title":"Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer","volume":"23","author":"Fu","year":"2024","journal-title":"Mol Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41467-024-55330-7","article-title":"Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer","volume":"16","author":"Klein","year":"2025","journal-title":"Nat Commun"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s42003-024-06087-8","article-title":"Pancreatic cancer-associated fibroblasts modulate immunosuppressive tumor-associated macrophages through sialic acid-Siglec interactions","volume":"7","author":"Boelaars","year":"2024","journal-title":"Commun Biol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"217699","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - exploring the space","volume":"622","author":"Brautigam","year":"2025","journal-title":"Cancer Lett"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1573522","DOI":"10.3389\/fimmu.2025.1573522","article-title":"Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma","volume":"16","author":"Ramesh","year":"2025","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1323198","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41571-025-01077-z","article-title":"The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities","volume":"22","author":"Kung","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"101621","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/cells13010101","article-title":"Chimeric antigen receptor T cell therapy for pancreatic Cancer: a review of current evidence","volume":"13","author":"Czaplicka","year":"2024","journal-title":"Cells"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/cancers17040589","article-title":"Advancing immunotherapy in pancreatic Cancer: a brief review of emerging adoptive cell therapies","volume":"17","author":"Sherpally","year":"2025","journal-title":"Cancers (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","article-title":"CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:30:16Z","timestamp":1786620616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":47,"alternative-id":["10.3389\/fmed.2026.1900701"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1900701","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1900701"}}